To receive daily emails from Amazing Health Advances to your inbox CLICK HERE
Desperate for a Cure, Great Hope is Rising for This New Cancer Treatment
Rafael Pharmaceuticals president David Polinsky said CPI-613 offers new hope to cancer patients in a way no other drug can.
(Newark, NJ) — [CBN News] There isn't a person in America who hasn't been touched by cancer. Although the diagnosis often elicits fear, a new cancer drug is providing never before seen hope to people with this dreaded disease. (Screengrab via CBN News)
Scientists at Rafael Pharmaceuticals believe their new drug, CPI-613, is a breakthrough for people suffering from some of the most devastating types of cancer, such as pancreatic, lymphoma and lung.
CPI-613 is administered to cancer patients intravenously in a hospital. Each infusion lasts up to two hours.
Cancer Cells Are Different From Healthy Cells
CPI-613 was developed as part of Rafael's proprietary Altered Energy Metabolism Directed (AEMD) drug platform. The drug is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, an indispensable process essential to tumor cell multiplication and survival, selectively in cancer cells.
Cancer cells have different nutritional needs than healthy cells. CPI-613 targets cancer metabolism, which is a relatively new way of treating the disease.
Rafael Pharmaceuticals president David Polinsky said CPI-613 offers new hope to cancer patients in a way no other drug can. "I think at Raphael we're really on the cusp of some very exciting times ahead in the field of oncology." (Screengrab via CBN News)
Clinical Trials Proving Successful
CPI-613 has performed very well in clinical trials and could be on the market as soon as next year. However, some people with cancer can't wait that long. Those people who can't wait might qualify for what's called "compassionate use," according to Rafael Pharmaceuticals Chief Operating Officer Sanjeev Luther. "We currently do not charge for compassionate use. We actually believe in helping, and so we currently give our drug without charge for compassionate use."
CPI-613 reportedly has fewer side effects than other cancer drugs. Earlier this year, the Food and Drug Administration gave approval for the drug to move further into human testing.
Click here to continue reading.